The Cancer Drug Development Forum – CDDF is the platform for all stakeholders involved in the development of cancer drugs.

Accelerating the Development and Delivery of

Effective Oncology Treatments

to Patients

 

Cancer Drug Development Forum (CDDF) is a neutral, non–competitive platform

for multi-stakeholder discussions and collaboration in the development of cancer drugs.

 

CANCER DRUG DEVELOPMENT FORUM

The leading non-competitive drug development platform working to stimulate the advancement and accessibility of cancer treatment.

Unique Multi-Stakeholder Platform

Patients

Patients are the cornerstone of CDDF’s mission and central to our multi-stakeholder discussions. Patients and advocacy groups are invited to join the CDDF multi-stakeholder community and make their voices heard. Check out collaborative opportunities and grants available to patients.

Industry

The CDDF provides the healthcare industry with unique opportunities to collaborate with diverse stakeholders and take part in open dialogue to accelerate oncology drug development. Discover the CDDF Industry Membership Program and engage with key experts in oncology.

Academia

The CDDF fosters advancement and innovation in cancer research by creating a collaborative platform for academics to share knowledge and expertise with a multi-stakeholder audience. Join CDDF’s discussions on the latest developments and explore opportunities to contribute.

Regulators & HTAs

The CDDF convenes discussions on key topics in oncology, fostering a balanced exchange of perspectives. Regulators and HTA agencies can gain valuable insights and stay informed on emerging trends through our productive dialogue. Explore collaboration opportunities and join our community.

CDDF Job Opening – Event Coordinator

[📣 🔔CDDF Job Opening - Event Coordinator] Are you passionate about organizing impactful events and ready to make a difference in the fight against cancer? The Cancer Drug Development Forum (CDDF), a not-for-profit organization dedicated to accelerating cancer drug...

Key Takeaways from the CDDF Multi-Stakeholder Workshop on New Modalities in Oncology Drug Development (31 March – 1 April 2025)

The first day of the CDDF Multi-Stakeholder Workshop on New Modalities in Oncology Drug Development set the stage for insightful discussions on the evolving landscape of oncology treatments. The event brought together experts from regulatory bodies, pharmaceutical...

Key Takeaways from the CDDF Live Webinar on EU HTA Regulation (March 2025)

🔔 📢 The Cancer Drug Development Forum (CDDF) held a live webinar on “EU HTA Regulation.” on 12 March at 17:00 CET. This webinar featured a lively discussion between Michael Berntgen (EMA, NL), Niklas Hedberg (TLV, SE) and Dr. Vanessa Schaub (Roche, CH). Dr. Rosa...

Article: The Importance of Diversity in Clinical Research

[📢Article on the Importance of Diversity in Clinical Research ] Yesterday our former Board Member; John Smyth, published an interesting article on the Importance of Diversity in Clinical Research in the ASCO Post. This topic was at the heart of the discussions, which...

CDDF Job Opening – Director of Operations

[📣 🔔CDDF Job Opening - Director of Operations] The Cancer Drug Development Forum (CDDF) is seeking a dynamic and experienced Director of Operations to join our team and lead the day-to-day operations of the association. As a key member of the leadership team, the...

Key Takeaways from the Annual Conference 2025 (3-5 Feb 2025, Noordwijk aan Zee) Day 2

The second day of the CDDF Annual Conference on Challenges, Advances, and Open Questions in Global Cancer Drug Development and Clinical Trial brought together a diverse group of stakeholders into open, constructive discussions in order to improve cancer drug...

Key Takeaways from the Annual Conference 2025 (3-5 Feb 2025, Noordwijk aan Zee)

The first day of the CDDF Annual Conference on Challenges, Advances, and Open Questions in Global Cancer Drug Development and Clinical Trial brought together a diverse group of stakeholders into open, constructive discussions in order to improve cancer drug...

ACT EU workshop on ICH E6 R3 – broadcast details and Slido

Dear participants, Thank you for your interest in participating in upcoming ACT EU workshop on ICH E6 R3. Due to the high level of interest, the programme committee has decided that participants joining remotely should access the broadcast the event, accessible via...

Forwarding Information – public consultation on the ICH M15 Guideline on general principles for model-informed drug development

The European Medicines Agency has published for public consultation the ICH M15 Guideline on general principles for model-informed drug development. This guideline provides general recommendations for planning, model evaluation, and documentation of evidence derived...

ICH E6(R3) final principles & Annex 1 published

We are pleased to announce that the ICH E6(R3) principles and Annex 1 have been finalised and published on the ICH website. This is a rewrite and reorganisation of the R2 version of the guideline on Good Clinical Practice (GCP), which sets international standards for...

CDDF Webinar: Bayesian Approaches in Drug Development (July 2024)

The recording of the recent CDDF webinar on Bayesian Approaches in Drug Development is available here. Enjoy the insightful talks from DRob Hemmings (Consilium, UK) followed by an interactive Q&A session.

CDDF & Oncology News

Check out the recent updates within the CDDF and the latest news in the community of cancer research

CDDF Brochure

Access the CDDF Brochure here

 

Join the CDDF community to find ways to accelerate oncology drug development and deliver optimal treatment to cancer patients

COLLABORATION IS THE KEY

TO IMPROVING OUTCOMES

FOR CANCER PATIENTS

Cancer Drug Development Forum asbl
Registered office: c/o BLSI, Clos Chapelle-aux-Champs 30, 1200 Woluwe Saint Lambert, Belgium
Register of legal entities: the French Speaking Enterprise Court in Brussels
Enterprise number: 738.523.752

Privacy Policy

info@cddf.org
Tel: +32 2 880 62 70